• • The CFO-BTO core-shell nanoparticles exhibit a ~99.4 nm magnetostrictive core and ~7 nm piezoelectric shell, enabling efficient strain-mediated magnetoelectric coupling under an AMF of 20 mT at 1.18 kHz, which is critical for wireless deep-tissue stimulation without invasive electrodes.
• • Microfluidic fabrication yields NPCbots with >85% cell viability, preserving stem cell multipotency, which is essential for scalable clinical manufacturing and consistent therapeutic outcomes.
• • Wireless AMF stimulation (20 mT, 1.18 kHz) triggers localized electrical signals that induce rapid neural differentiation and structural reconnection, leading to accelerated functional motor recovery in preclinical SCI models, demonstrating a non-invasive alternative to implanted electrodes.
• • The platform integrates microfluidic biofabrication, magnetoelectric nanomaterials, precise micro-positioning, and wireless electro-stimulation, offering a minimally invasive paradigm that addresses the limitations of biochemical inducers and traditional electrical stimulation, with potential for translation to human patients pending further safety and scalability evaluations.